The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2021 | Sequential CD19 and BCMA CAR-T
Chengcheng Fu, MD, PhD, The First Affiliated Hospital of Soochow University, Suzhou, China, discusses investigations of sequential CAR-T infusion, whereby CD19 CAR-T is given and followed up by infusion of a B-cell maturation antigen (BCMA)-targeting CAR. Chengcheng Fu goes on to highlight the high expense of this kind of therapy and the potential of frontline CAR-T. This interview took place during the 2nd Immune Effector Cell Therapy in MM Workshop in Boston, MA.
